David Carlile

3.3k total citations
55 papers, 2.3k citations indexed

About

David Carlile is a scholar working on Oncology, Pathology and Forensic Medicine and Pharmacology. According to data from OpenAlex, David Carlile has authored 55 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Oncology, 20 papers in Pathology and Forensic Medicine and 15 papers in Pharmacology. Recurrent topics in David Carlile's work include Lymphoma Diagnosis and Treatment (18 papers), CAR-T cell therapy research (16 papers) and Pharmacogenetics and Drug Metabolism (15 papers). David Carlile is often cited by papers focused on Lymphoma Diagnosis and Treatment (18 papers), CAR-T cell therapy research (16 papers) and Pharmacogenetics and Drug Metabolism (15 papers). David Carlile collaborates with scholars based in United Kingdom, Switzerland and United States. David Carlile's co-authors include J. Brian Houston, J. Brian Houston, Martin K. Bayliss, Katayoun Zomorodi, Brian G. Lake, Nancy Hakooz, Alan R. Boobis, John C. Lipscomb, Philippe Beaune and Robert J. Edwards and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and Blood.

In The Last Decade

David Carlile

54 papers receiving 2.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Carlile United Kingdom 24 1.1k 844 534 517 370 55 2.3k
Nahoko Kaniwa Japan 32 1.2k 1.1× 613 0.7× 436 0.8× 985 1.9× 95 0.3× 113 3.4k
Shuiying Hu United States 32 1.7k 1.5× 313 0.4× 314 0.6× 1.3k 2.5× 332 0.9× 94 3.5k
J. Greg Slatter United States 21 666 0.6× 540 0.6× 134 0.3× 762 1.5× 162 0.4× 50 1.9k
Joseph A. Ware United States 25 999 0.9× 385 0.5× 159 0.3× 814 1.6× 247 0.7× 70 2.2k
Laurent Salphati United States 30 1.7k 1.6× 935 1.1× 103 0.2× 876 1.7× 225 0.6× 67 2.9k
Paul Martin United Kingdom 25 799 0.7× 383 0.5× 123 0.2× 570 1.1× 131 0.4× 50 2.2k
David Jones United States 29 819 0.7× 679 0.8× 121 0.2× 792 1.5× 77 0.2× 58 2.4k
Stijn L.W. Koolen Netherlands 25 1.1k 1.0× 171 0.2× 108 0.2× 545 1.1× 231 0.6× 155 2.3k
Csilla Özvegy‐Laczka Hungary 31 2.5k 2.3× 350 0.4× 89 0.2× 1.3k 2.6× 187 0.5× 71 3.4k
Peter Stopfer Germany 28 1.5k 1.3× 178 0.2× 154 0.3× 878 1.7× 159 0.4× 69 2.6k

Countries citing papers authored by David Carlile

Since Specialization
Citations

This map shows the geographic impact of David Carlile's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Carlile with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Carlile more than expected).

Fields of papers citing papers by David Carlile

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Carlile. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Carlile. The network helps show where David Carlile may publish in the future.

Co-authorship network of co-authors of David Carlile

This figure shows the co-authorship network connecting the top 25 collaborators of David Carlile. A scholar is included among the top collaborators of David Carlile based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Carlile. David Carlile is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jamois, Candice, David C. Turner, Leonid Gibiansky, et al.. (2025). Tocilizumab Dosing for Management of T Cell‐Engaging Bispecific Antibody‐Related CRS in Patients With R/R B‐Cell NHL. Clinical Pharmacology & Therapeutics. 118(4). 917–927. 1 indexed citations
2.
Phillips, Tycel, Carmelo Carlo‐Stella, Franck Morschhauser, et al.. (2024). Glofitamab monotherapy in patients with heavily pretreated relapsed/refractory (R/R) mantle cell lymphoma (MCL): Updated analysis from a phase I/II study.. Journal of Clinical Oncology. 42(16_suppl). 7008–7008. 7 indexed citations
3.
Phillips, Tycel, Carmelo Carlo‐Stella, Franck Morschhauser, et al.. (2024). Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II Study. Journal of Clinical Oncology. 43(3). 318–328. 18 indexed citations
4.
5.
6.
Carlo‐Stella, Carmelo, Cyrus Khan, Martin Hutchings, et al.. (2021). ABCL-360: Glofitamab Step-Up Dosing (SUD): Updated Efficacy Data Show High Complete Response Rates in Heavily Pretreated Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) Patients (Pts). Clinical Lymphoma Myeloma & Leukemia. 21. S394–S394. 2 indexed citations
7.
Flanagan, Talia, James Mann, Εva Karlsson, et al.. (2019). Impact of Acid-Reducing Agents on Gastrointestinal Physiology and Design of Biorelevant Dissolution Tests to Reflect These Changes. Journal of Pharmaceutical Sciences. 108(11). 3461–3477. 22 indexed citations
8.
Elks, Cathy E., Paul Martin, David Carlile, et al.. (2017). Pharmacokinetics and pharmacogenetics of the MEK1/2 inhibitor, selumetinib, in Asian and Western healthy subjects: a pooled analysis. European Journal of Clinical Pharmacology. 73(6). 717–726. 12 indexed citations
9.
10.
Jänne, Pasi A., Michel M. van den Heuvel, Fabrice Barlési, et al.. (2017). Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non–Small Cell Lung Cancer. JAMA. 317(18). 1844–1844. 249 indexed citations
11.
Jänne, Pasi A., Michel M. van den Heuvel, Fabrice Barlési, et al.. (2016). Selumetinib in combination with docetaxel as second-line treatment for patients with KRAS-mutant advanced NSCLC: Results from the phase III SELECT-1 trial. Annals of Oncology. 27. vi583–vi583. 10 indexed citations
12.
Kuhlmann, Olaf, David Carlile, Johannes Noé, & Darren Bentley. (2014). Interaction potential of Carmegliptin with P-glycoprotein (Pgp) transporter in healthy volunteers. PubMed. 3(1). 28–37. 3 indexed citations
13.
Phelan, Mary C., Judith Anzures‐Cabrera, David Carlile, et al.. (2013). Effect of Hepatic and Renal Impairment on the Pharmacokinetics of Dalcetrapib. Clinical Pharmacokinetics. 52(4). 255–265. 10 indexed citations
14.
Bentley, Darren, et al.. (2012). Evidence of a Drug–Drug Interaction Linked to Inhibition of Ester Hydrolysis by Orlistat. Journal of Cardiovascular Pharmacology. 60(4). 390–396. 22 indexed citations
15.
Hakooz, Nancy, Kiyomi Ito, Helen Gill, et al.. (2006). Determination of a Human Hepatic Microsomal Scaling Factor for Predicting in Vivo Drug Clearance. Pharmaceutical Research. 23(3). 533–539. 60 indexed citations
16.
17.
Worboys, Philip & David Carlile. (2001). Implications and consequences of enzyme induction on preclinical and clinical drug development. Xenobiotica. 31(8-9). 539–556. 29 indexed citations
18.
Houston, J. Brian & David Carlile. (1997). Prediction of Hepatic Clearance from Microsomes, Hepatocytes, and Liver Slices. Drug Metabolism Reviews. 29(4). 891–922. 247 indexed citations
19.
Houston, J. Brian & David Carlile. (1997). Incorporation of in vitro drug metabolism data into physiologically-based pharmacokinetic models. Toxicology in Vitro. 11(5). 473–478. 27 indexed citations
20.
Zomorodi, Katayoun, David Carlile, & J. Brian Houston. (1995). Kinetics of diazepam metabolism in rat hepatic microsomes and hepatocytes and their use in predicting in vivo hepatic clearance. Xenobiotica. 25(9). 907–916. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nahoko Kaniwa Breakdown of academic impact, for papers by Shuiying Hu Breakdown of academic impact, for papers by J. Greg Slatter Breakdown of academic impact, for papers by Joseph A. Ware Breakdown of academic impact, for papers by Laurent Salphati Breakdown of academic impact, for papers by Paul Martin Breakdown of academic impact, for papers by David Jones Breakdown of academic impact, for papers by Stijn L.W. Koolen Breakdown of academic impact, for papers by Csilla Özvegy‐Laczka Breakdown of academic impact, for papers by Peter Stopfer
Rankless by CCL
2026